Navigation Links
New MedPredict Report Highlights Recent Advances in Management of Malignant Hematology
Date:1/15/2010

SCOTTSDALE, Ariz., Jan. 15 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing therapies to treat hematologic malignancies.  These reports are based on primary interviews conducted with hematologists from North America immediately following the American Society of Hematology (ASH) annual meeting.

This report, entitled "Thought Leader Insight & Analysis – Malignant Hematology," includes analysis of new research in Multiple Myeloma, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Lymphoma, and Chronic Myelogenous Leukemia.  

"This report reflects on and analyzes the most important data presented at ASH, and clarifies the ways these data will change clinical practice," according to Jeff Berk, MedPredict president. "A key focus of the report is Multiple Myeloma (MM), which is being transformed into a chronic, but still life threatening disease.  The most exciting advances presented at ASH included both identifying the most effective combinations for induction therapy, and in establishing a role and practice standard for maintenance therapy in MM."

According to one MM Thought Leader interviewed for this report:  "I think the message was very positive in regards that maintenance matters, choice of induction strategy matters with less toxicity being important, and staying on treatment of some form or another is very critical."

The expert panel also discusses novel compounds in development for various hematologic malignancies, and the hurdles they will need to overcome to become viable options in this market.  

Companies and partnerships mentioned in this report includes: Allos, Ambit, Amgen, Arno Therapeutics, Antisoma, Biogen Idec/Elan, Biotest/ImmunoGen, Bristol-Myers Squibb, Bristol-Myers Squibb/Facet, Celgene, Celgene/Gloucester, Cephalon, ChemGenex, Cyclacel, Eisai, Genmab, Genzyme, Genzyme/Anormed, Genzyme/Bayer HealthCare Pharmaceuticals, Geron/Merck, GlaxoSmithKline, GlaxoSmithKline/Genmab, ImmunoGen, Immunomedics/Nycomed, Incyte, Keryx, Merck, Milteni Biotec, Novartis, Novartis/Vernalis, OXiGENE, PDL Biopharma, Proteolix/Onyx, Rigel, Seattle Genetics, Syndax, and Takeda/Millennium.

This report can be purchased by contacting MedPredict (www.medpredict.com).  

About MedPredict

MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories.  Based on primary interviews with these thought leaders, MedPredict publishes periodic reports to keep clients up-to-date on emerging trends and competitive activity.  The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict

RELATED LINKS
http://www.medpredict.com

'/>"/>

SOURCE MedPredict
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report
2. Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010
3. New Report by BioTrends Research Group To Highlight The Launch Of ACTEMRA (tocilizumab)
4. Does the MS Market Need Another Interferon? Neurologists Provide Insight in the Wave One Report of LaunchTrends: EXTAVIA
5. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
6. BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties
7. Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016
8. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
9. Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition]
10. Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015
11. Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):